Cue Biopharma, Inc.
Symbol: CUE (NASDAQ)
0.72
▲ (0.46%) 0.003
Company Description:
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Key Stats
- Today's Open: $0.71
- Today's High: $0.727
- Today's Low: $0.699
- Today's Volume: 396.05K
- Yesterday Close: $0.7187
- Yesterday High: $0.7274
- Yesterday Low: $0.6875
- Yesterday Volume: 221.80K
- Last Min Volume: 1
- Last Min High: $0.722
- Last Min Low: $0.722
- Last Min VWAP: $0.722
Company Profile
- Name: Cue Biopharma, Inc.
- Website: https://www.cuebiopharma.com
- Listed Date: 2018-01-02
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001645460
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $55.23M
- Round Lot: 100
- Outstanding Shares: 76.85M
- Asset Type: CS
RECENT FILINGS FOR CUE
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-29 | 8-K | View |
| 2025-08-12 | S-8 | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-07-01 | 8-K | View |
| 2025-06-10 | 8-K | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 3 | View |
| 2025-05-27 | DEFA14A | View |
| 2025-05-16 | SCHEDULE 13G/A | View |
| 2025-05-12 | 10-Q | View |
| 2025-05-12 | 8-K | View |
| 2025-04-25 | ARS | View |
| 2025-04-25 | DEF 14A | View |
| 2025-04-25 | DEFA14A | View |
| 2025-04-15 | 8-K | View |
| 2025-04-15 | 424B5 | View |
| 2025-04-14 | 424B5 | View |
| 2025-04-14 | 8-K | View |
| 2025-04-14 | PRE 14A | View |
Latest News on CUE